Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.
Patel MR, Johnson M, Winer I, Arkenau HT, Cook N, Samouëlian V, Aljumaily R, Kitano S, Duffy C, Ge M, Elgadi M, Siu LL. Patel MR, et al. Among authors: cook n. Cancer Immunol Immunother. 2024 Mar 30;73(5):89. doi: 10.1007/s00262-024-03654-0. Cancer Immunol Immunother. 2024. PMID: 38554156 Free PMC article. Clinical Trial.
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.
Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, Brenner A, Cook N, Lopez J, Pant S, Frankel A, Schmid P, Moore K, McCulloch W, Grimmer K, O'Farrell M, Kemble G, Burris H. Falchook G, et al. Among authors: cook n. EClinicalMedicine. 2021 Mar 30;34:100797. doi: 10.1016/j.eclinm.2021.100797. eCollection 2021 Apr. EClinicalMedicine. 2021. PMID: 33870151 Free PMC article.
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Choudhury AD, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, Martin-Liberal J, Linch M, Heath EI, Baird RD, García-Carbacho J, Quintela-Fandino M, Barry ST, de Bruin EC, Colebrook S, Hawkins G, Klinowska T, Maroj B, Moorthy G, Mortimer PG, Moschetta M, Nikolaou M, Sainsbury L, Shapiro GI, Siu LL, Hansen AR. Choudhury AD, et al. Among authors: cook n. Clin Cancer Res. 2022 Jun 1;28(11):2257-2269. doi: 10.1158/1078-0432.CCR-21-3087. Clin Cancer Res. 2022. PMID: 35247924 Free PMC article. Clinical Trial.
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.
Robbrecht DGJ, Lopez J, Calvo E, He X, Hiroshi H, Soni N, Cook N, Dowlati A, Fasolo A, Moreno V, Eskens FALM, de Bono JS. Robbrecht DGJ, et al. Among authors: cook n. Br J Cancer. 2021 Jan;124(2):391-398. doi: 10.1038/s41416-020-01100-3. Epub 2020 Oct 6. Br J Cancer. 2021. PMID: 33020594 Free PMC article. Clinical Trial.
1,397 results